Doximity (DOCS) Q4 2026 earnings review
Growth Hits a Wall as AI Investments Crush Near-Term Profitability
Doximity's Q4 results confirmed the market's worst fears regarding pharma budget headwinds. Revenue growth decelerated sharply to just 5% YoY, a brutal drop from the 23% seen two quarters ago. While the company boasts record engagement with over 800,000 active prescribers and rapidly growing Clinical AI usage, these tools are not yet monetizing fast enough to offset the core slowdown. Heavy investments in AI and surging stock-based compensation caused Net Income to collapse 69% YoY. FY27 guidance is sobering, implying single-digit revenue growth and an outright contraction in Adjusted EBITDA, marking a painful transition phase for the digital health leader.
🐂 Bull Case
Over 800,000 active prescribers used workflow tools in Q4, and prompts per user nearly doubled between January and April alone. The engagement moat is deepening.
Despite GAAP net income collapsing due to R&D and SBC, Free Cash Flow still grew 11% YoY in Q4 to $107.3M, driven by strong working capital management and subscription renewals.
🐻 Bear Case
The macro headwinds identified in Q3—specifically delayed pharma budgets linked to Most Favored Nation (MFN) policy uncertainty—have materialized forcefully, dragging Q4 growth to a mere 5%.
FY27 guidance projects an 8% decline in Adjusted EBITDA. The company is funding its 'Third Act' (AI) through significant margin compression, requiring investors to wait for an undefined monetization timeline.
⚖️ Verdict: 🔴
Bearish. While product engagement is undeniably strong, Doximity is experiencing a severe break in its financial trajectory. The transition from a high-growth, high-margin software platform to an AI-investment story with single-digit top-line growth fundamentally alters the investment thesis.
Key Themes
Pharma Budget Headwinds Paralyze Top-Line Growth
The warning signs from Q3 have come to fruition. Management previously noted that uncertainty surrounding Most Favored Nation (MFN) agreements with the White House caused major pharma clients to delay up-front commitments. The result is a sharp deceleration: Revenue growth went from 23% in 26Q2, to 10% in 26Q3, to just 5% in 26Q4. This is a dramatic slowdown for a company that grew 20% in FY25.
AI Investments and SBC Crush Profitability
GAAP Net Income fell 69% YoY to $19.1M, reversing the company's long-standing trend of robust bottom-line expansion. The culprit is the rapid scaling of the AI organization following the Pathway acquisition. R&D expenses jumped 58% YoY in Q4. Furthermore, Stock-Based Compensation (SBC) doubled from $18.1M in 25Q4 to $36.7M in 26Q4, significantly diluting earnings quality.
Explosive Clinical AI Engagement
Despite the financial lag, product adoption is accelerating. A record 800,000 active prescribers used Doximity's workflow tools in Q4, and nearly half of those utilized the Clinical AI features. The velocity of usage is also compounding, with AI prompts per user nearly doubling between January and April. This massive, engaged user base remains Doximity's most powerful asset.
Strategic API Integrations Unlock New Workflows
Management announced new partnerships with Aledade and Photon. These integrations embed Doximity's Clinical AI Suite directly into the workflows of thousands of independent practices, enabling seamless in-workflow prescribing for the first time. This represents a critical pivot from a standalone app to a fully integrated enterprise infrastructure layer.
Major C-Suite Overhaul During a Pivot
At a critical juncture for the company, Doximity announced significant leadership changes: Matt Sonefeldt takes over as CFO (replacing Anna Bryson, who previously went on medical leave), and Dr. Steve Zatz steps in as the new President. Executing a major strategic pivot toward AI while shuffling key leadership introduces elevated execution risk.
Cash Conversion Defies Net Income Drop
Despite the severe contraction in GAAP profitability, cash generation remains a core strength. Free Cash Flow grew 11% in Q4 ($107.3M) and 19% for the full year ($317.5M), representing an exceptional 49% FCF margin for FY26. This limits downside risk and provides ample capital to fund both AI investments and share repurchases.
Data Contradiction: High Engagement vs Lagging Monetization
There is a stark divergence between the operational narrative and financial reality. While management champions AI adoption (prompts doubling, half of prescribers using tools), this record engagement failed to translate into Q4 revenue beats or a strong FY27 outlook. The lack of near-term monetization for the 'Third Act' remains the primary friction point for investors.
Other KPIs
Reversing. SBC surged 68% from $72.4M in FY25. For Q4 alone, it reached $36.7M, representing 25% of total revenue. Management previously warned that AI talent retention and the Pathway acquisition would drive SBC into the 'high teens' as a percentage of revenue, but it has drastically exceeded that projection in the current quarter.
Accelerating. Up 58% YoY from $24.8M in 25Q4. This aggressive spend is directly tied to the buildout of the Clinical AI suite and infrastructure costs. The cost of running high-compute language models is structurally lowering Doximity's operating margins.
Guidance
Decelerating. The midpoint of $670M implies just 3.9% YoY growth. This confirms that the Q4 slowdown was not an anomaly, but the new baseline for the upcoming year, drastically trailing the 13% growth achieved in FY26 and the 20% growth in FY25.
Reversing. The midpoint of $329M implies an 8.0% YoY decline from the $357.8M achieved in FY26. This marks the first time Doximity is guiding for negative annual EBITDA growth, reflecting the intense cost burden of its AI rollout.
Decelerating. The midpoint of $151.5M implies just 3.8% YoY growth compared to 26Q1 ($145.9M). This sets the tone for a sluggish start to the fiscal year as pharma marketing budgets remain constrained.
Decelerating. The midpoint implies a 45.5% margin, slightly up from 26Q4's 45.3%, but severely depressed compared to the 54.7% margin achieved in 26Q1. The structural reset in profitability is fully priced into the first quarter.
Key Questions
Timeline to AI Monetization
With prompts doubling and 50% of prescribers using Clinical AI, when will we see the launch of paid, commercial AI tiers to offset the core pharma advertising slowdown?
Pharma Budget Visibility
Is the mid-single-digit revenue guidance for FY27 purely a function of delayed budgets due to MFN policies, or are clients fundamentally reallocating digital ad spend away from HCP platforms?
Stock-Based Compensation Ceiling
SBC reached 25% of revenue in Q4, well above prior commentary suggesting it would plateau in the 'high teens'. Has the cost of retaining elite AI talent permanently altered the company's long-term dilution profile?
Aledade and Photon Economics
How does the economic model work for the new embedded API partnerships with Aledade and Photon? Will these generate SaaS-like recurring revenue, or are they primarily intended to drive platform stickiness?